首页|期刊导航|肝胆胰外科杂志|肝脾联合切除术治疗CNLCⅠb期单发肝细胞癌合并门静脉高压症的多中心回顾性队列研究

肝脾联合切除术治疗CNLCⅠb期单发肝细胞癌合并门静脉高压症的多中心回顾性队列研究OA

A multi-center retrospective cohort study on hepatectomy combined with splenectomy for patients with CNLC stageⅠb solitary hepatocellular carcinoma complicated by portal hypertension

中文摘要英文摘要

目的 探讨肝脾联合切除术在中国肝癌临床分期(CNLC)Ⅰb期单发肝细胞癌(HCC)合并门静脉高压症(PH)患者中的安全性和远期生存获益.方法 回顾性分析2015年1月至2020年12月在我国8家医疗中心收治的167例CNLCⅠb期单发HCC合并PH患者的临床资料,其中53例行肝脾联合切除术(H-S组),114例行单纯肝切除术(H-O组).采用倾向性评分匹配(PSM)平衡两组的基线特征后,每组各纳入39例,比较两组患者的围手术期安全性指标及生存结局.结果 在PSM匹配后的队列中,H-S组与H-O组术后30 d内病死率[5.1%(2/39)vs 7.7%(3/39),χ2<0.001,P=1.000]和严重并发症发生率[20.5%(8/39)vs 12.8%(5/39),χ2=0.369,P=0.543]差异无统计学意义,但H-S组门静脉血栓发生率更高[20.5%(8/39)vs 0,χ2=6.825,P=0.009].生存分析显示,相较于H-O组,H-S组术后5年总体生存(OS)率(46.8%vs 39.9%,χ2=7.717,P=0.005)和无复发生存(RFS)率(27.8%vs 10.5%,χ2=5.094,P=0.024)更高,中位OS时间(59.0个月vs 41.0个月)和中位RFS时间(40.0个月vs 22.0个月)明显延长.多因素Cox回归分析显示,联合脾切除术是CNLCⅠb期单发HCC合并PH患者OS(HR=0.48,95%CI 0.31-0.73,P<0.001)和RFS(HR=0.55,95%CI 0.37-0.81,P=0.003)的独立保护因素.结论 肝脾联合切除术在CNLCⅠb期单发HCC合并PH患者中具有可接受的围手术期安全性,并可显著改善患者的远期生存,但需重视术后门静脉血栓的防治.

Objective To evaluate the perioperative safety and long-term survival benefits of hepatectomy combined with splenectomy in patients with China Liver Cancer Staging(CNLC)system stage Ⅰb solitary hepatocellular carcinoma(HCC)complicated by portal hypertension(PH).Methods This multicenter retrospective cohort study included 167 patients with CNLC stage Ⅰb solitary HCC complicated by PH who underwent curative-intent surgery at 8 medical centers in China from January 2015 to December 2020.Among them,53 patients underwent hepatectomy combined with splenectomy(H-S group),and 114 patients underwent hepatectomy alone(H-O group).To minimize selection bias,propensity score matching(PSM)was performed to balance baseline characteristics,including liver function status,PH-related parameters,tumor features,and surgical variables,resulting in 39 well-matched patient pairs respectively.Perioperative outcomes and survival were compared between the two groups.Results In the PSM cohort,there were no significant differences between the H-S group and H-O group in 30-day postoperative mortality[5.1%(2/39)vs 7.7%(3/39),χ2<0.001,P=1.000]or the incidence of major complications[20.5%(8/39)vs 12.8%(5/39),χ2=0.369,P=0.543].However,the H-S group had a significantly higher incidence of postoperative portal vein thrombosis[20.5%(8/39)vs 0,χ2=6.825,P=0.009].Long-term survival analysis showed that the H-S group achieved higher 5-year overall survival(OS)rate(46.8%vs 39.9%,χ2=7.717,P=0.005)and 5-year recurrence-free survival(RFS)rate(27.8%vs 10.5%,χ2=5.094,P=0.024),longer median OS time(59.0 months vs 41.0 months)and median RFS time(40.0 months vs 22.0 months).Multivariate Cox regression analysis identified synchronous splenectomy as an independent protective factor for patients with CNLC Stage Ⅰb solitary HCC complicated by PH,associated with improved OS(HR=0.48,95%CI 0.31 to 0.73,P<0.001)and RFS(HR=0.55,95%CI 0.37 to 0.81,P=0.003).Conclusion Hepatectomy combined with splenectomy demonstrates acceptable perioperative safety in carefully selected patients with CNLC stageⅠb solitary HCC complicated by PH and is associated with significant improvements in long-term survival outcomes.Nevertheless,the increased vigilance and preventive strategies for postoperative portal vein thrombosis are warranted.

胡瀚龙;余德才;汪斌;张志伟;陈孝平;邵天胤;程琪;张占国;何松青;李德宇;向邦德;周存才;李波

华中科技大学同济医学院附属同济医院肝胆胰外科,湖北 武汉 430030南京大学医学院附属鼓楼医院肝胆外科,江苏 南京 210008湖北省人民医院肝胆外科,湖北 武汉 430060华中科技大学同济医学院附属同济医院肝胆胰外科,湖北 武汉 430030华中科技大学同济医学院附属同济医院肝胆胰外科,湖北 武汉 430030华中科技大学同济医学院附属同济医院肝胆胰外科,湖北 武汉 430030华中科技大学同济医学院附属同济医院肝胆胰外科,湖北 武汉 430030华中科技大学同济医学院附属同济医院肝胆胰外科,湖北 武汉 430030广西医科大学第一附属医院肝胆胰外科,广西 南宁 530021河南省人民医院肝胆胰外科,河南 郑州 450003广西医科大学附属肿瘤医院肝胆胰外科,广西 南宁 530200江西省肿瘤医院肝胆外科,江西 南昌 330029四川大学华西医院肝胆外科,四川 成都 610041

医药卫生

肝细胞癌门静脉高压症肝脾联合切除术门静脉血栓倾向性评分匹配多中心研究

hepatocellular carcinomaportal hypertensionhepatectomy combined with splenectomyportal vein thrombosispropensity score matchingmulti-center study

《肝胆胰外科杂志》 2026 (3)

161-172,180,13

华中科技大学同济医学院附属同济医院临床研究领航项目(2019CR202)湖北陈孝平科技发展基金会肝胆胰恶性肿瘤研究基金多中心重大专项项目(CXPJJH11800001-2018104).

10.11952/j.issn.1007-1954.2026.03.002

评论